AMARILLO, Texas, May 18, 2017 /PRNewswire/ — Maxor National Pharmacy Services, LLC («Maxor»), today announced that Vertex Pharmaceuticals Inc. has now included Maxor Specialty, comprised of IV Solutions and Pharmaceutical Specialties («PSI»), in its specialty pharmacy network. Effectively immediately, patients may now utilize Maxor Specialty for Orkambi® and Kalydeco®, two leading medications used in the treatment of certain types of Cystic Fibrosis («CF»).

Maxor Logo

«We are extremely proud and excited to begin providing Orkambi® and Kalydeco® to our Cystic Fibrosis patients. As a leader in the Cystic Fibrosis community, our focus has always been on providing complete and comprehensive care to our patients. CF patients often take more than 8 different medications a day, and access to the Vertex products now allows our pharmacists to help CF patients obtain and manage all of their prescribed medications through our specialty pharmacy,» said Mike Ellis, CEO of Maxor.

Maxor Specialty is a national leader in providing pharmacy services to physicians and their patients with rare and complex diseases such as Cystic Fibrosis, and serves patients with rare diseases in all 50 states. Providing specialty, respiratory, and infusion therapy services since 1986, Maxor Specialty addresses all aspects of specialty and infusion pharmacy care with a personalized high-touch approach to clinical management.

About Maxor
Established in 1926, Maxor is a leading pharmacy services platform that consists of three primary business segments: (i) MaxorPlus, providing client and patient-focused URAC accredited pharmacy benefit management («PBM») services with desired clinical outcomes; (ii) Maxor Specialty, IV Solutions, and Pharmaceutical Specialties, providing specialty pharmacy, respiratory, and home infusion services; accredited by the Accreditation Commission for Health Care (Maxor Specialty), The Joint Commission (IV Solutions), and URAC for specialty pharmacy (IV Solutions – Lubbock, Pharmaceutical Specialties, and Maxor Pharmacies dba Maxor Specialty); and (iii) Maxor Pharmacy Management and Consulting Services, providing on-site outpatient pharmacy management, 340B audits, and consulting services to hospitals, health systems, Federally Qualified Health Plans, DSH hospitals, and self-funded employer groups.

These segments offer complementary services that aim to improve the health of patients and effectively manage pharmacy expenditures for Maxor’s patients and clients. More information on Maxor can be found by visiting


To view the original version on PR Newswire, visit:

SOURCE Maxor National Pharmacy Services, LLC